Skip to main content

Market Overview

Juno Therapeutics Upgraded By Vetr Top Raters, 100% Of Crowd Bullish


Shares of Juno Therapeutics Inc (NASDAQ: JUNO) have lost nearly 20 percent since the start of 2016 and around 25 percent over the past year. The stock's underperformance likely prompted Vetr top raters to recognize value in a beaten up stock.

Vetr top raters upgraded Juno Therapeutics' stock rating to 4.5-stars out of a possible 5-stars. In fact, shares of Juno Therapeutics have risen to $33.91 since the prior rating of 4.0-stars was issued just two days ago.

Related link: Here's how crowdsourced ratings can beat the market.

In addition to an upgrade to bull-territory, 100 percent of the crowd's ratings are bullish and the crowd sourced price target of $39.61 implies a potential upside of nearly 15 percent.


Related Articles (JUNO)

View Comments and Join the Discussion!

Posted-In: health care stocks Vetr Vetr Crowd Vetr Top RatersAnalyst Color Crowdsourcing Analyst Ratings General

Latest Ratings

RAINGuggenheimInitiates Coverage On26.0
SWIMTruist SecuritiesInitiates Coverage On37.0
AGTICitigroupInitiates Coverage On19.0
IMPLGuggenheimInitiates Coverage On32.0
KNBECitigroupInitiates Coverage On21.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at